Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges

mAbs

Volumn 2, Issue 6, 2010, Pages 670-681

  Fontoura, Paulo ^a,b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Alemtuzumab; Antibody; Monoclonal; Multiple sclerosis; Natalizumab; Rituximab; Therapy

Indexed keywords

ACT 128800; ALEMTUZUMAB; BAF 312; BAPINEUZUMAB; BETA INTERFERON; BETA1A INTERFERON; CDP 323; CLADRIBINE; DACLIZUMAB; EFALIZUMAB; FINGOLIMOD; FIRATEGRAST; FUMARIC ACID DIMETHYL ESTER; LAQUINIMOD; MONOCLONAL ANTIBODY; NATALIZUMAB; OCRELIZUMAB; PLACEBO; RITUXIMAB; TERIFLUNOMIDE; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; USTEKINUMAB;

AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG BINDING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LOW DRUG DOSE; LUPUS VULGARIS; LYMPHOCYTE MIGRATION; LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS;

EID: 78649670034     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.6.13270     Document Type: Review

References (71)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372:1502-17.
2. Lublin F. History of modern multiple sclerosis therapy. J Neurol 2005; 252:3-9.
3. Sospedra M, Martin R. Immunology of multiple sclerosis. Ann Rev Immunol 2005; 23:683-747.
4. Bermel RA, Fisher E, Cohen JA. The use of MR imaging as an outcome measure in multiple sclerosis clinical trials. Neuroimaging Clin N Am 2008; 18:687-701.
5. Menge T, Weber MS, Hemmer B, Kieseier BC, von Budingen HC, Warnke C, et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008; 68:2445-68.
6. Clerico M, Contessa G, Durelli L. Interferon-beta1a for the treatment of multiple sclerosis. Expert Opin Biol Ther 2007; 7:535-42.
7. Wiendl H, Hohlfeld R. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology 2009; 72:1008-15.
8. Klawiter EC, Cross AH, Naismith RT. The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%? Neurology 2009; 73:984-90.
9. Steinman L, Martin R, Bernard C, Conlon P, Oksenberg JR. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Ann Rev Neurosci 2002; 25:491-505.
10. Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis - a multifaceted adversary. Nat Rev Drug Discov 2008; 7:909-25.
11. Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008; 29:558-65.
12. Cohen JA. Emerging therapies for relapsing multiple sclerosis. Arch Neurol 2009; 66:821-8.
13. Bielekova B, Becker BL. Monoclonal antibodies in MS: mechanisms of action. Neurology 2010; 74:31-40.
14. Petereit HF, Rubbert-Roth A. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler 2009; 15:189-92.
15. Rudick RA, Mi S, Sandrock AW Jr. LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Expert Opin Biol Ther 2008; 8:1561-70.
16. Fontoura P, Steinman L. Nogo in multiple sclerosis: growing roles of a growth inhibitor. J Neurol Sci 2006; 245:201-10.
17. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. (11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9:363-72.
18. Steinman L. The use of monoclonal antibodies for treatment of autoimmune disease. J Clin Immunol 1990; 10:30-8.
19. Hohlfeld R, Wekerle H. Drug insight: using monoclonal antibodies to treat multiple sclerosis. Nat Clin Pract Neurol 2005; 1:34-44.
20. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47:1531-4.
21. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002; 16:183-200.
22. Steinman L. Immune therapy for autoimmune diseases. Science 2004; 305:212-6.
23. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Ann Rev Immunol 2007; 25:821-52.
24. El-Behi M, Rostami A, Ciric B. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharm 2010;5:189-97.
25. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008; 7:796-804.
26. Elliott M, Benson J, Blank M, Brodmerkel C, Baker D, Sharples KR, et al. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann NY Acad Sci 2009; 1182:97-110.
27. Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 2008; 7:538-47.
28. Buttmann M, Rieckmann P. Treating multiple sclerosis with monoclonal antibodies. Expert Rev Neurother 2008; 8:433-55.
29. Rose JW, Foley JF, Carlson NG. Monoclonal antibody treatments for multiple sclerosis. Curr Treat Options Neurol 2009; 11:211-20.
30. Ransohoff RM. Natalizumab for multiple sclerosis. New Engl J Med 2007; 356:2622-9.
31. Johnson KP. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis. Neurologist 2007; 13:182-7.
32. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005; 26:485-95.
33. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha4beta1 integrin. Nature 1992; 356:63-6.
34. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005; 4:510-8.
35. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 2006; 354:899-910.
36. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New Engl J Med 2006; 354:911-23.
37. Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64:1336-42.
38. + T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006; 63:1383-7.
39. Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006; 59:743-7.
40. Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59:748-54.
41. + T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008; 65:1596-603.
42. Li YY, Perez HD, Zollner TM. Fatalities in natalizumab treatment - a 'no go' for leukocyte recirculation approaches? Expert Opin Ther Targets 2006; 10:489-99.
43. Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007; 6:431-41.
44. Clifford DB, Deluca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9:438-46.
45. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 71:766-73.
46. Brickelmaier M, Lugovskoy A, Kartikeyan R, Reviriego-Mendoza MM, Allaire N, Simon K, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Ch 2009; 53:1840-9.
47. Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004; 306:1380-3.
48. Schweikert A, Kremer M, Ringel F, Liebig T, Duyster J, Stuve O, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2009; 66:403-6.
49. Bergamaschi R, Montomoli C. Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? Mult Scler 2009; 15:1532-3.
50. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. P Natl Acad Sci USA 2006; 103:5941-6.
51. Oh U, Blevins G, Griffith C, Richert N, Maric D, Lee CR, et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol 2009; 66:471-9.
52. Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. P Natl Acad Sci USA 2004; 101:8705-8.
53. Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009; 66:483-9.
54. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9:381-90.
55. Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253:98-108.
56. Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354:1691-5.
57. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New Engl J Med 2008; 359:1786-801.
58. Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, Shawcross J, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119:2052-61.
59. Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Invest Dr 2008; 9:1206-15.
60. Castillo J, Milani C, Mendez-Allwood D. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Inv Drug 2009; 18:491-500.
61. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells and multiple sclerosis. Lancet Neurol 2008; 7:852-8.
62. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008; 4:557-67.
63. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130:1089-104.
64. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128:2705-12.
65. McLaughlin KA, Wucherpfennig KW. B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol 2008; 98:121-49.
66. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New Engl J Med 2008; 358:676-88.
67. Martin MP, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, et al. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 2009; 66:1016-20.
68. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66:460-71.
69. Pittock SJ. Neuromyelitis optica: a new perspective. Sem Neurol 2008; 28:95-104.
70. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65:1443-8.
71. Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008; 8:391-7.